Edition#3: 10-3-2025

1. Sponsor Portfolio Shifts

Roche halts Phase II in Alzheimer’s candidate.
Why it matters: Expect heightened caution around neurodegenerative investments — vendors in imaging, biomarkers, and patient recruitment should focus on differentiators.
👉 Read more »

AstraZeneca expands oncology trials in Asia-Pacific.
Why it matters: Rising demand for site capacity in Korea, Taiwan, and Australia; CROs and vendors with local presence should position aggressively.
👉 Read more »

2. Clinical Ops Leadership Moves

Bristol Myers Squibb names new EVP of Clinical Development.
Why it matters: Leadership changes often reset vendor strategies — connect past trial results to upcoming portfolio needs.
👉 Read more »

Sanofi hires former Novartis exec as Head of Clinical Ops.
Why it matters: Expect operational shifts in outsourcing approach; fresh leaders often evaluate supplier rosters within 90 days.
👉 Read more »

3. Vendor Exec Hires

Medidata brings in ex-IQVIA leader as Chief Commercial Officer.
Why it matters: Signals stronger push to integrate data/AI into trial sales pitches; competitors should anticipate new bundled offerings.
👉 Read more »

Clario appoints new CFO from life sciences PE background.
Why it matters: Financial leadership with PE focus suggests M&A readiness; partners should monitor for upcoming acquisitions.
👉 Read more »